



**Thursday, April 9, 2015**  
**7:00 a.m. to 8:30 a.m.**  
**Cannon Health Building**  
**Room 125**

**Board Members Present:**

**Tony Dalpiaz, PharmD.**  
**Michael Symond, M.D.**  
**Keith Tolman, M.D.**  
**Mr. Kumar Shah**

**Jennifer Brinton, MD**  
**George Hamblin, PharmD**  
**Susan Siegfroid, M.D**

**Board Members Excused:**

**Kyle Jones, M.D.**  
**Jay Aldus, DDS**

**Mark Balk, PharmD.**

**Dept. of Health/Div. of Health Care Financing Staff Present:**

**Robyn Seely, Pharm.D**  
**Trevor Smith C.Ph.T.**  
**Heather Santacruz, R.N .**

**Lisa Hunt, RPh**  
**Merelynn Berrett, R.N.**  
**Alyssa Pitts, R.N.**

**Other Individuals Present:**

**Gary Oderda, UofU**  
**Melanie Wallentine, UDOH/PRISM**  
**Devin Stack, UofU**  
**Karen Campbell, Allergan**  
**Linda Morris RN, UDOH**

**Scott Clegg, Lilly**  
**Candice Nielson, UofU**  
**Jane Stephen, Allergan**  
**Sean McGarr, Actavis**

---

**Meeting conducted by: Tony Dalpiaz, Pharm.D.**

---

- 1. Welcome** – Tony Dalpiaz opened the meeting.
- 2. Housekeeping** – Robyn Seely welcomed everyone to the meeting and reminded everyone to sign in. She said that there is no petitions today. She also welcomed the new Prior Authorization nurse, Alyssa Pitts who recently joined Utah Medicaid.
- 3. P&T Committee report** – Lisa Hunt said that the next P&T committee meeting will discussed diuretic agents in last month's meeting. She said that for April's meeting, the P&T committee will review SGLT-2 products and hold the annual training.
- 4. Approval of prior meeting minutes** – Keith Tolman made a motion to approve the February meeting minutes. Michael Symond seconded the motion. All in favor.

5. **PRISM Announcement** – Melanie Wallentine from the UDOH PRISM claims processing system, which is currently under development, passed out materials requesting providers to perform testing of the new system. She said that anyone interested can email [prism@utah.gov](mailto:prism@utah.gov) with questions or to ask about testing opportunities.
6. **Botulinum toxin PA requirement review** – Linda Morris RN, asked the board to have consistent criteria between medical and pharmacy policy on the procedure code 64115. She said that the problem with this code is when the drug is used in a surgery center or ambulatory surgical centers, which require the use of anesthesia and other extremely costly services. She asked that the PA to state the drug can't be used more frequently than every twelve weeks and also have the requirement to fail on the use of a prescribed drug for migraine prior to the use of the Botulinum toxin.
  - a. Robyn Seely presented proposed PA criteria sheets with the changes discussed to the board.
  - b. Jennifer Brinton said that when she uses this drug in her practice, she said that the 12 week time frame is appropriate and what is done with her patients. She also said that the requirement for failure on a prescribed migraine medication is not unreasonable and thinks the proposed criteria are good.
  - c. Keith Tolman asked a question about FDA guidelines. Lisa Hunt answered that as a government program; Medicaid is required to follow FDA guidelines, which the PA will cover. If a doctor wished to use the drug for off label use, they may submit documentation and get an DUR approval for an exception.
  - d. Mike Symond said that he believes the FDA guidelines are good to follow in this case, and the PA should be modified as discussed.
  - e. George Hamblin made a motion to approve the proposed criteria for use on pharmacy and medical PAs. Jennifer Brinton seconded the motion. All in favor.

#### 7. 9 month review – Insulin Pens

- a. Robyn Seely said that there are no concerns with the PA put on insulin pens 9 months ago. She said that 72% of the PAs for insulin pens have been approved.
- b. She said that the PA criteria currently on the pens continue.

8. **Afrezza inhaled insulin** – Gary Oderda from the University of Utah DRRC presented drug information including disease symptoms, studies, side effects, indications and other information about Afrezza inhaled insulin. Data was also presented about the utilization of the drugs in the Utah Medicaid population in previous years.

#### 9. Public Comment

- a. No Public Comment.

#### 10. Board Discussion

- a. Keith Tolman asked about pulmonary cancer instances for patients with diabetes with no smoking history. Gary Oderda answered saying that the risk is very

- minimal, but the drug still has a black box warning.
- b. Robyn Seely recommended to the board to have no PA criteria on the drug for now. She wants to watch utilization and potentially bring it back to the board in the future if needed.
  - c. Mike Symond had concerns about the small dosing pack size, so patients could require a lot of medication to achieve a high dosage of medication. He worried that this could inflate costs over the price of injected insulin.
  - d. Mike Symond made a motion to allow for a period of 9 months for observation with no PA requirements, and then return the topic to the DUR board. Kumar Shah seconded the motion. All in favor.

## **11. Meeting Adjourned**

The next DUR Board meeting is scheduled for Thursday, May 14<sup>th</sup>. Tentative schedule is to discuss Grastek, Ragwitek and Oralair products will be discussed.

Minutes prepared by Trevor Smith.

Recording available upon request, send email to [medicaidpharmacy@utah.gov](mailto:medicaidpharmacy@utah.gov)